Development of bispecific T cell engagers: harnessing quantitative systems pharmacology
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of bispecific T cell engagers: harnessing quantitative systems pharmacology
Authors
Keywords
-
Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-10-17
DOI
10.1016/j.tips.2023.09.009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanistically Modeling Peripheral Cytokine Dynamics Following Bispecific Dosing in Solid Tumors
- (2023) Jared Weddell CPT-Pharmacometrics & Systems Pharmacology
- The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
- (2023) Mirco J. Friedrich et al. CANCER CELL
- Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL
- (2023) Monica E. Susilo et al. CTS-Clinical and Translational Science
- Glofitamab: First Approval
- (2023) Matt Shirley DRUGS
- Strategies for clinical dose optimization of T cell-engaging therapies in oncology
- (2023) Kathryn Ball et al. mAbs
- In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome
- (2023) Jeroen H. A. Creemers et al. Nature Communications
- Epcoritamab: First Approval
- (2023) James E. Frampton DRUGS
- Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance
- (2023) Can Liu et al. eLife
- Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy
- (2023) Yue Lang et al. Frontiers in Immunology
- Tebentafusp: First Approval
- (2022) Sohita Dhillon DRUGS
- Outcomes of blinatumomab based therapy in children with relapsed, persistent, or refractory acute lymphoblastic leukemia: a multicenter study focusing on predictors of response and post-treatment immunoglobulin production
- (2022) Mohammed F Essa et al. PEDIATRIC HEMATOLOGY AND ONCOLOGY
- T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities
- (2022) Patrick A. Baeuerle et al. CURRENT OPINION IN ONCOLOGY
- Mosunetuzumab: First Approval
- (2022) Connie Kang DRUGS
- Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma
- (2022) R. E. Abrams et al. Scientific Reports
- Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma
- (2022) Tomoki Yoneyama et al. PLoS Computational Biology
- Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas
- (2022) Tommy Li et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Current landscape and future directions of bispecific antibodies in cancer immunotherapy
- (2022) Jing Wei et al. Frontiers in Immunology
- Teclistamab: First Approval
- (2022) Connie Kang DRUGS
- Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
- (2021) Martin Hutchings et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
- (2021) Zheng Tian et al. Journal of Hematology & Oncology
- History and Future Perspectives on the Discipline of Quantitative Systems Pharmacology Modeling and Its Applications
- (2021) Karim Azer et al. Frontiers in Physiology
- Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
- (2021) Martin Hutchings et al. LANCET
- Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
- (2021) Lihua E. Budde et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab
- (2021) Nicolas Frances et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- The Drug-Dosing Conundrum in Oncology — When Less Is More
- (2021) Mirat Shah et al. NEW ENGLAND JOURNAL OF MEDICINE
- Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics
- (2020) Cris Kamperschroer et al. Journal of Immunotoxicology
- Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans
- (2020) Xiling Jiang et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach
- (2020) Teilo H Schaller et al. Journal for ImmunoTherapy of Cancer
- A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor
- (2020) Huilin Ma et al. AAPS Journal
- Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology
- (2020) Alison Betts et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A rapid, sensitive, and reproducible in vivo PBMC humanized murine model for determining therapeutic‐related cytokine release syndrome
- (2020) Chunting Ye et al. FASEB JOURNAL
- Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling
- (2020) Iraj Hosseini et al. npj Systems Biology and Applications
- A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®
- (2019) Alison Betts et al. AAPS Journal
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity
- (2019) Ji Li et al. Science Translational Medicine
- Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity
- (2018) Olivia Campagne et al. CLINICAL CANCER RESEARCH
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
- (2017) Haleh Saber et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Mechanistic Projection of First-in-Human Dose for Bispecific Immunomodulatory P-Cadherin LP-DART: An Integrated PK/PD Modeling Approach
- (2016) X Chen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- An FDA oncology analysis of immune activating products and first-in-human dose selection
- (2016) Haleh Saber et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Blinatumomab: First Global Approval
- (2015) Mark Sanford DRUGS
- Using quantitative systems pharmacology for novel drug discovery
- (2015) Violeta I Pérez-Nueno Expert Opinion on Drug Discovery
- Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS
- (2015) Miguel F. Sanmamed et al. SEMINARS IN ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started